These include alterations such as in ERBB2 (HER2), which is frequently amplified in aggressive breast cancer subtypes, or PTEN (phosphatase and tensin homolog), a tumor suppressor gene that, when deleted or mutated, can lead to the activation of the PI3K/AKT signaling pathway. This evidence concerns the gene ERBB2 and breast cancer.